

## **C-Path is proud to share our responses to the FDA draft guidance, Digital Health Technologies for Remote Data Acquisition in Clinical Investigations**

The Clinical Outcomes Assessment (COA), Critical Path for Parkinson's Digital Drug Development (3DT) Initiative, and Type 1 Diabetes (T1D) Consortia all contributed to this effort, resulting in a combined set of comments on behalf of C-Path. By bringing together stakeholders across industry, regulatory agencies, patient groups, academic researchers and clinicians, disease foundations and other organizations aiming to improve patients' lives, C-Path hopes these comments will provide helpful feedback on how DHT (Digital Health Technologies) are used to accelerate a path to a healthier world.

We thank and commend FDA for the opportunity to provide comments and look forward to future developments in this area.

[Digital Health Technologies for Remote Data Acquisition in Clinical Investigations](#)